MGTX NASDAQ
MeiraGTx Holdings plc
1W: -4.6%
1M: -5.4%
3M: +27.4%
YTD: +21.5%
1Y: +72.5%
3Y: +35.6%
5Y: -27.0%
$9.24
-0.25 (-2.63%)
Weekly Expected Move ±6.3%
$8
$9
$9
$10
$11
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (34)
Can MeiraGTx Holdings PLC (MGTX) Stock Double? Cash Runway Offers a Hint
MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Lags Revenue Estimates
MeiraGTx GAAP EPS of -$0.57 misses by $0.18, revenue of $0.29M
MeiraGTx Reports First Quarter 2026 Financial and Operational Results
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know
Enanta Pharmaceuticals (ENTA) Moves 5.3% Higher: Will This Strength Last?
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates
Will MeiraGTx Holdings PLC (MGTX) Report Negative Q1 Earnings? What You Should Know
HC Wainwright Has Bearish Forecast for MeiraGTx Q1 Earnings
OCGN Gene Therapy Pipeline: Key 2026-27 Catalysts Ahead
OCGN Gene Therapy Pipeline: Key 2026-27 Catalysts Ahead
Equities Analysts Set Expectations for MeiraGTx Q1 Earnings
MeiraGTx (MGTX) Soars 6.8%: Is Further Upside Left in the Stock?
MeiraGTx (NASDAQ:MGTX) Sees Strong Trading Volume on Analyst Upgrade
Evercore Maintains Positive Stance on MeiraGTx Holdings plc (MGTX) Amid Sector Revisions
12 Health Care Stocks Moving In Thursday's Intraday Session
MeiraGTx eyes $100M equity offering after gene therapy deal with J&J
Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson
12 Health Care Stocks Moving In Thursday's Pre-Market Session
MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)
MeiraGTx Holdings PLC (NASDAQ:MGTX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Strength Seen in MeiraGTx (MGTX): Can Its 6.2% Jump Turn into More Strength?
Alexandria Forbes Sells 62,000 Shares of MeiraGTx (NASDAQ:MGTX) Stock
MeiraGTx Holdings PLC (MGTX) Q4 Earnings and Revenues Surpass Estimates
MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results
MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results
X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates
MeiraGTx Holdings PLC (NASDAQ:MGTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates
AnaptysBio, Inc. (ANAB) Q4 Earnings and Revenues Top Estimates
ZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic Atrophy
AMH Equity Ltd Invests $658,000 in MeiraGTx Holdings PLC $MGTX
MeiraGTx Holdings PLC (NASDAQ:MGTX) Given Average Rating of “Moderate Buy” by Analysts